Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

4.8%

3 terminated/withdrawn out of 62 trials

Success Rate

84.2%

-2.4% vs industry average

Late-Stage Pipeline

29%

18 trials in Phase 3/4

Results Transparency

6%

1 of 16 completed trials have results

Key Signals

10 recruiting1 with results

Enrollment Performance

Analytics

N/A
23(48.9%)
Phase 4
16(34.0%)
Phase 2
5(10.6%)
Phase 3
2(4.3%)
Phase 1
1(2.1%)
47Total
N/A(23)
Phase 4(16)
Phase 2(5)
Phase 3(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (62)

Showing 20 of 62 trials
NCT03812016Not ApplicableRecruiting

A Feedback-enabled Magnetic Device for Temporary Management of Blepharoptosis

Role: lead

NCT05125939Completed

Can Overall Adenoma Detection Rate Replace Screening Adenoma Detection Rate ? Multicenter Study

Role: collaborator

NCT07761234Not ApplicableCompleted

Exploring the Effectiveness of an Application Intervention on Cognitive, Learning Self-Efficacy,and Clinical Reasoning of Nurses Regarding Delirium Education in the Intensive Care Unit

Role: collaborator

NCT06727864Phase 3Recruiting

Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial

Role: collaborator

NCT07641465Not ApplicableActive Not Recruiting

Effects of Jive Dance Training on Lower Limb Muscle Strength

Role: lead

NCT01194518Not ApplicableCompleted

Exploring Life Experience and Lifestyle Intervention Program Among Patients With CKD

Role: collaborator

NCT06456450Recruiting

Taiwan Severe Asthma Biologic Registry

Role: collaborator

NCT06198699Not ApplicableRecruiting

Effects of Jing Si Herbal Tea on Quality of Life and Sleep in Dementia and Their Caregivers

Role: collaborator

NCT04496882Phase 4Active Not Recruiting

Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue

Role: collaborator

NCT06482411Completed

Risk Factors Affect Weight Loss Outcomes After Treatment.

Role: lead

NCT03443492Phase 2Completed

SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer

Role: collaborator

NCT03848260Not ApplicableSuspended

A Real-Time Magnetic Device Prototype for Temporary Management of Paralytic Lagophthalmos

Role: lead

NCT07091942Recruiting

Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

Role: collaborator

NCT05863208Not ApplicableRecruiting

Artificial Intelligence-assisted Colonoscopy With or Without Endocuff Vision

Role: lead

NCT03753074Phase 4Active Not Recruiting

Effectiveness of TAF in Reducing Clinical Events in CHB Patients Beyond Treatment Indications by Current Guidelines

Role: collaborator

NCT03024684Phase 4Active Not Recruiting

Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

Role: collaborator

NCT06476470Recruiting

Taiwan Interstitial Lung Disease Multi-center Investigation and Registry

Role: collaborator

NCT06447441Not ApplicableNot Yet Recruiting

Clinical Outcomes Of Mega-dosage Supplementations Of Cholecalciferol In Critically Ill Patients With Sepsis

Role: collaborator

NCT06460402Not ApplicableEnrolling By Invitation

Ice Therapy and Warm Baths for Hemorrhoidectomy Wound Care

Role: lead

NCT06420388Not ApplicableRecruiting

2% Lidocaine Gel in Reducing Postoperative Pain Following Haemorrhoidectomy

Role: lead